*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Adult Aged Aged 80 and over Female Humans Male Middle Aged Urinary Bladder Neoplasms/*radiotherapy Bladder neoplasm Bladder preservation Cis Chemoradiotherapy Radiotherapy T1 Bladder cancer

Cystectomy/*methods Humans Organ Sparing Treatments/*methods Treatment Outcome Urinary Bladder Neoplasms/*surgery Bladder preservation High-grade non-muscle-invasive bladder cancer Meta-analysis Radical cystectomy PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.